Innovative Research Award
Safeena Kulsum
Narayana Hrudayalaya Ltd, India
Safeena Kulsum is a researcher affiliated with Narayana Hrudayalaya Ltd in India, with a documented research profile indexed in Scopus under Author ID 57190759680. The supplied profile records six documents, 173 citations, and an h-index of 4, providing a bibliometric basis for describing her scholarly activity. Her stated subject area is Cancer Biomarkers, a field concerned with measurable biological characteristics that can support the understanding and management of disease. Biomarkers may include molecules or molecular signatures detected in tissues, blood, or other biological materials and can contribute to diagnostic, prognostic, and therapeutic decision-making.[1]
Abstract
The Innovative Research Award profile recognizes the documented academic record of Safeena Kulsum in the area of Cancer Biomarkers. The available bibliometric information identifies Narayana Hrudayalaya Ltd as her institutional affiliation and records six Scopus-indexed documents. The supplied metrics further indicate 173 citations and an h-index of 4, which together provide measurable indicators of scholarly visibility within the indexed research record. These indicators are presented descriptively and should be interpreted in relation to publication age, field-specific citation practices, authorship, and database coverage.[2]
Keywords
- Cancer Biomarkers
- Oncology Research
- Molecular Biomarkers
- Precision Oncology
- Liquid Biopsy
- Tumour Biology
- Cancer Research
Introduction
Cancer biomarkers occupy an important position at the interface of molecular biology, pathology, translational research, and clinical oncology. A biomarker can provide information about a biological process, disease state, treatment response, or other clinically relevant characteristic. The National Cancer Institute notes that biomarkers may be used in understanding disease and evaluating how the body responds to treatment.[1] Their interpretation therefore depends on both biological validity and the context in which testing is performed.
Research Profile
The supplied Scopus record associates Safeena Kulsum with six documents and 173 citations, producing a reported h-index of 4. These metrics offer a concise representation of the indexed publication and citation record available through the supplied author profile. Citation-based indicators are useful for describing research visibility, but they do not independently measure methodological quality, clinical significance, originality, or the practical influence of individual studies. Accordingly, the metrics are best considered alongside publication content and disciplinary context.[2]
Research Contributions
Within the stated field, research contributions may be considered through the development, evaluation, or application of biomarkers that improve understanding of cancer biology. Biomarker investigations can address molecular alterations associated with tumour development, disease progression, therapeutic response, or recurrence. The literature also demonstrates increasing interest in circulating tumour DNA and other liquid-biopsy analytes as tools for longitudinal molecular assessment. These developments emphasize the importance of robust sampling, reproducible laboratory methods, and appropriate clinical validation.[5]
Publications
The supplied Scopus information reports six indexed documents associated with Author ID 57190759680. Because individual publication titles, journal names, publication years, authorship positions, and article identifiers were not supplied, this page does not infer or fabricate a publication list. The Scopus author profile is provided as the primary external source for reviewing the indexed record. Researchers and award reviewers can use that profile to verify individual documents and associated bibliometric information.
Research Impact
The reported citation count of 173 and h-index of 4 indicate that the supplied Scopus record has received measurable scholarly attention. Citation counts can reflect the use of published findings by subsequent researchers, although their interpretation varies considerably between disciplines and publication periods. In cancer research, highly active fields can exhibit different citation patterns from specialized clinical or laboratory areas. Consequently, bibliometric indicators should be interpreted as descriptive evidence rather than as a standalone assessment of research quality.
Award Suitability
The documented research profile is relevant to an academic recognition framework focused on oncology and cancer research because the stated subject area is Cancer Biomarkers. The combination of a defined institutional affiliation, six indexed documents, 173 citations, and an h-index of 4 provides objective bibliometric information for consideration. Award assessment should nevertheless incorporate article-level evidence, research originality, methodological contribution, authorship role, and relevance to the award criteria. These factors help distinguish quantitative visibility from substantive scientific contribution.
Conclusion
Safeena Kulsum is presented here as a researcher affiliated with Narayana Hrudayalaya Ltd, India, with a stated specialization in Cancer Biomarkers. The supplied Scopus record reports six documents, 173 citations, and an h-index of 4 under Author ID 57190759680. These indicators establish a concise bibliometric profile that can support academic recognition while remaining subject to database coverage and periodic updates. More detailed evaluation would require examination of the underlying publications and verified research contributions.
External Links
References
-
- National Cancer Institute. (n.d.). Biomarker. NCI Dictionary of Cancer Terms.
https://www.cancer.gov/publications/dictionaries/cancer-terms/def/biomarker
- Elsevier. (n.d.). Scopus author details: Safeena Kulsum, Author ID 57190759680. Scopus.
https://www.scopus.com/pages/authors/57190759680
- Valpione, S., Clipson, A., Rothwell, D. G., Dive, C., & Mouliere, F. (2026). Advancing the applications of liquid biopsies in oncology. Nature Reviews Genetics.
https://doi.org/10.1038/s41576-026-00974-y
- Crowley, E., Di Nicolantonio, F., Loupakis, F., & Bardelli, A. (2013). Liquid biopsy: monitoring cancer-genetics in the blood. Nature Reviews Clinical Oncology, 10, 472–484.
https://doi.org/10.1038/nrclinonc.2013.110
- Siravegna, G., Marsoni, S., Siena, S., & Bardelli, A. (2017). Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology, 14, 531–548.
https://doi.org/10.1038/nrclinonc.2017.14